Advanced search
Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 18, 2011 - Issue sup1: XIIth International Symposium on Amyloidosis From Molecular Mechanisms Towards the Cure of Systemic Amyloidoses
Submit an article Journal homepage
112
Views
2
CrossRef citations to date
0
Altmetric
Opening lecture

Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse

A. MoscettiA.O. Sant'Andrea, U.O.S. Diagnosi e Cura delle Discrasie Plasmacellulari e delle Amiloidosi, Rome, Italy
,
F. SaltarelliA.O. Sant'Andrea, U.O.S. Diagnosi e Cura delle Discrasie Plasmacellulari e delle Amiloidosi, Rome, Italy
,
M. P. BianchiA.O. Sant'Andrea, U.O.S. Diagnosi e Cura delle Discrasie Plasmacellulari e delle Amiloidosi, Rome, Italy
,
B. MonarcaA.O. Sant'Andrea, U.O.S. Diagnosi e Cura delle Discrasie Plasmacellulari e delle Amiloidosi, Rome, Italy
,
L. De BiaseA.O. Sant'Andrea, U.O.S. Diagnosi e Cura delle Discrasie Plasmacellulari e delle Amiloidosi, Rome, Italy
,
R. PorriniA.O. Sant'Andrea, U.O.S. Diagnosi e Cura delle Discrasie Plasmacellulari e delle Amiloidosi, Rome, Italy
,
G. AntolinoA.O. Sant'Andrea, U.O.S. Diagnosi e Cura delle Discrasie Plasmacellulari e delle Amiloidosi, Rome, Italy
&
G. La VerdeA.O. Sant'Andrea, U.O.S. Diagnosi e Cura delle Discrasie Plasmacellulari e delle Amiloidosi, Rome, Italy
 show all
Pages 152-154 | Published online: 18 Aug 2011

References

  • Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59.
  • Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276–4282.
  • Dubrey SW, Cha K, Anderson J, Chamarti B, Reisinger J, Skinner M, Falk RH. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Q J Med 1998;91:141–157.
  • Iggo N, Littlewood T, Winearls CG. Prospects for effective treatment of AL amyloidosis? Q J Med 2000;93:257–260.
  • Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica 2009;94:1044–1048.
  • Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–2498.
  • Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006;106:1316–1319.
  • Catley L, Tai YT, Chauhan D, Anderson KC. Perspectives for combination therapy to overcome drugresistant multiple myeloma. Drug Resist Update 2005;8:205–218.
  • Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005;104:2141–2148.
  • Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351–1358.
  • Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008;93:295–298.
  • Lamm W, Willenbacher W, Lang A, Zojer N, Müldür E, Ludwig H, Schauer-Stalzer B, Zielinski CC, Drach J. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol 2011;90:201–206.
  • Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Definition of Organ Involvement and Treatment Response in Immunoglobulin Light Chain Amyloidosis (AL): A Consensus Opinion From the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79:319–328.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.